Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of⦠read more
Healthcare
Biotechnology
3 years
USD
Exclusive to Premium users
$34.10
Price+1.25%
$0.42
$493.939m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$1.400m
-
1y CAGR-
3y CAGR-
5y CAGR-$163.694m
-
1y CAGR-
3y CAGR-
5y CAGR-$10.80
-
1y CAGR-
3y CAGR-
5y CAGR$68.559m
$212.118m
Assets$143.559m
Liabilities$7.510m
Debt3.5%
-
Debt to EBITDA-$140.133m
-
1y CAGR-
3y CAGR-
5y CAGR